Pulmonary arterial hypertension targeted for new treatment by University of 91Ö±²¥ scientists
Scientists at the University of 91Ö±²¥, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).